If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Neuroimaging Technique Shows Bapineuzumab’s Potential in Alzheimer’s Disease NEW YORK -- March 1, 2010 -- A neuroimaging technique known as carbon-11-labelled Pittsburgh compound B (¹¹C-PiB PET) shows that a new investigational drug, bapineuzumab, reduces amyloid-beta deposits in the brain by about 25% compared with placebo in patients who have mild-to-moderate Alzheimer’s disease. As such, ¹¹C-PiB PET imaging might be useful for assessing which drugs work to prevent the build up of amyloid-beta deposits in the brains of people living with Alzheimer’s disease. These are the conclusions of an article published online first and appearing in the April issue of The Lancet Neurology. Evidence suggests that accumulation of amyloid-beta plaques in the brain is central to the development of Alzheimer’s disease, but until recently confirmation of the presence of these plaques was only possible at autopsy. A new technique has been developed that measures amyloid-beta load by use of PET scans and the radiotracer ¹¹C-PiB, which binds to amyloid-beta plaques and shows the amount and distribution of amyloid deposits in the brains of living people. Using this technique, research has shown that patients with Alzheimer’s disease have about 2 times greater retention of ¹¹C-PiB in areas of the cerebral cortex that are targeted by amyloid deposits compared with healthy controls. It has been suggested that bapineuzumab might bind to amyloid-beta plaques and clear deposits from the brain to slow down disease progression in Alzheimer’s disease. In this phase 2 study, Juha Rinne, MD, University of Turku, Turku, Finland, and colleagues investigated whether bapineuzumab could reduce amyloid-beta load measured using ¹¹C-PiB PET imaging in cortical areas in patients with Alzheimer’s disease. A total of 28 patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive one of 3 doses of bapineuzumab (0.5, 1.0, 2.0 mg/kg) or placebo by intravenous infusion every 13 weeks for up to 6 infusions. ¹¹C-PiB PET scans were done at the start of the study and at weeks 20, 45, and 78. Findings showed that compared with the start of the study, treatment with bapineuzumab for 78 weeks led to a significant reduction in mean ¹¹C-PiB retention compared with placebo. The authors estimate that bapineuzumab treatment was associated with about a 25% reduction in amyloid-beta load over 78 weeks compared with placebo. ¹¹C-PiB retention increased in the placebo group relative to the start of the study, whereas it decreased in the bapineuzumab group. The difference in ¹¹C-PiB retention between the bapineuzumab and placebo groups was similar for each of the 3 doses, and the treatment difference increased over time, suggesting that greater differences in ¹¹C-PiB retention might be possible with extended treatment. Bapineuzumab treatment was generally well tolerated and adverse events were mild to moderate. However, 2 patients in the 2.0mg/kg bapineuzumab group experienced transient cerebral vasogenic oedema. The findings suggest that “monitoring of the effects of anti-amyloid-beta drugs on amyloid-beta deposition might be possible with radiotracers that bind to amyloid-beta in patients with Alzheimer’s disease or those at risk before the onset of clinical decline”, the authors wrote. “This technique offers the opportunity to test more directly the amyloid-beta hypothesis by confirming the ability of a particular drug to reduce or prevent amyloid-beta accumulation and to assess the effect this has on clinical outcomes.”
SOURCE: The Lancet Neurology
|
